GlycoNex Incorporation (TPEX:4168)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
23.50
+0.45 (1.95%)
Apr 29, 2026, 1:30 PM CST
42.86%
Market Cap 2.54B
Revenue (ttm) 37.86M
Net Income (ttm) -235.23M
Shares Out 108.21M
EPS (ttm) -2.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 160,769
Average Volume 176,036
Open 23.00
Previous Close 23.05
Day's Range 23.00 - 23.85
52-Week Range 16.55 - 30.95
Beta 0.63
RSI 42.59
Earnings Date May 13, 2026

About GlycoNex Incorporation

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company’s development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed antibody drug currently under the lead optimization stage; and GNX1021, a first-in-class antibody–drug conjugate currently under preclinical stage. It is a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4168
Full Company Profile

Financial Performance

In 2025, GlycoNex Incorporation's revenue was 37.86 million, an increase of 157.54% compared to the previous year's 14.70 million. Losses were -235.23 million, 2.40% more than in 2024.

Financial Statements

News

There is no news available yet.